No quarterly revenue total was found in FIRST TRACKS BIOTHERAPEUTICS, INC.'s SEC filings.
First Tracks Biotherapeutics, Inc. (TRAX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$17.1 million. As of Sep 30, 2026 it held $155.6 million in cash and investments and $3.8 million in total debt.
Revenue
—
Net income
$-31.36M
+6.0% vs prior quarter
Operating cash flow
$-17.05M
+46.6% vs prior quarter
Free cash flow
$-17.05M
+46.6% vs prior quarter
EPS
$-0.88
+7.4% vs prior quarter
Dividend per share
None
Shares outstanding
42.02M
+17.6% vs prior quarter
Net cash
$151.85M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TRAX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2091349
- Former names
- Biopharma Company, Inc. (until Feb 6, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
|---|---|---|---|
| Operating income | -$32.8M | -$34.9M | -$52.8M |
| Net income | -$31.4M | -$33.4M | -$50.5M |
| Diluted EPS | -$0.88 | -$0.95 | — |
| Operating cash flow | -$17.1M | -$31.9M | -$32.6M |
| Free cash flow | -$17.1M | -$31.9M | -$32.6M |
| Total assets | $170.5M | $183.1M | $290.6M |
| Stockholders' equity | $151.0M | $168.8M | $257.5M |
| Cash and investments | $155.6M | $168.0M | $286.5M |
| Total debt | $3.8M | $4.3M | $0 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 20, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 13, 2026 | Oct 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
All 98 First Tracks Biotherapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.